At 500+ trailing P/E and 90.7 forward P/E, this stock is priced for aggressive perfection despite razor-thin 0.60% operating margins and negative ROIC of -2.00%. The market cap of $3,729M against a 5.7 price-to-sales and 7.8 price-to-book multiple signals a growth premium that far outpaces current profitability. However, the 15.6 Altman Z-Score and massive 11.7 current ratio indicate extremely low near-term bankruptcy risk and substantial balance sheet liquidity. This is not a distressed story — it’s a high-multiple, high-expectation healthcare growth equity where safety comes from liquidity strength, not earnings power. The valuation implies the market is betting on a sharp earnings ramp, and at 90.7x forward earnings, there is absolutely no margin for operational missteps.